Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

Figure 1

Clinical efficacy over time through week 256. ACR20 (A), ACR50 (B), DAS28-CRP response (C), DAS28-CRP score <2.6 (D), DAS28-CRP score <3.2 (E), SDAI score ≤3.3 (F), and HAQ-DI improvement ≥0.25 (G). Data summarized for randomized patients receiving methotrexate at baseline, excluding one site, using intent-to-treat methodology, with replacement of missing data by last-observation-carried forward methodology and imputation with baseline median values, and nonresponder imputation for discontinuations due to unsatisfactory therapeutic effect. ACR20/50, ≥20%/50% improvement in the American College of Rheumatology response criteria; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; HAQ-DI, Health Assessment Questionnaire Disability Index; SDAI, Simplified Disease Activity Index.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us